The initial public offer of Supriya Lifescience Ltd was fully subscribed within few hours of opening for subscription on Thursday on the back of a strong response from retail investors.
The offer received bids for 1,92,28,860 shares as against 1,45,28,299 shares on offer, as per data with the NSE till 1236 hours.
The category for Retail Individual Investors (RIIs) was subscribed 6.68 times and those for non-institutional investors received 40 per cent subscription.
Supriya Lifescience's Initial Public Offer (IPO) has a fresh issue of up to Rs 200 crore and an offer for sale of up to Rs 500 crore. The price range is Rs 265-274 per share.
On Wednesday, the company raised Rs 315 crore from anchor investors.
The proceeds from the fresh issue will be used for funding capital expenditure requirements, repay debt and general corporate purpose.
Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients, with a focus on research and development.
ICICI Securities and Axis Capital are the managers to the offer.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)